XERS
Xeris Biopharma·NASDAQ
--
--(--)
--
--(--)
6.13 / 10
Outperform
Analyst coverage is limited but highly positive: one analyst issued a Strong‑Buy, giving a weighted rating of 5.00. Money‑flow score is 7.94, with positive inflows across block, medium, large and extra‑large investors, offset only by slight outflow in small caps.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-02
InstitutionHC Wainwright & Co.
Times predicted3
Historical Win Rate33.3%
Is money flowing into or out of XERS?
- XERS holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.13/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
